首页> 外文期刊>Journal of chemotherapy >Conclusions. Role of the oral Beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutics recommendations.
【24h】

Conclusions. Role of the oral Beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutics recommendations.

机译:结论。口服β-内酰胺类药物在治疗慢性支气管炎加重中的作用:关键分析和治疗建议。

获取原文
获取原文并翻译 | 示例
       

摘要

The GIARIR study group has made a critical analysis of the most recent scientific literature on acute bacterial exacerbations of chronic bronchitis (ABECB) with the aim of proposing therapeutic recommendations applicable to the current epidemiological situation in Italy. The international literature has indicated the scarcity of studies on the treatment of ABECB compared to an abundance of information regarding chronic obstructive pulmonary disease (COPD), of which ABECB is often considered the initial ore predisposing stage, even though a precise evolutionary correlation between these pathologies has not yet been demonstrated.ABECB is the principle cause of doctor visits, hospitalization and death in COPD patients. The natural course of the disease is characterized by the appearance of exacerbation episodes (a mean of two yearly). For this reason it is indispensable to prevent exacerbations, to treat them as quickly as possible, in order to minimize their negative effects on the respiratory tract and the patient's general health.
机译:GIARIR研究小组对有关慢性支气管炎急性细菌恶化的最新科学文献进行了批判性分析,旨在提出适用于意大利当前流行病学情况的治疗建议。国际文献表明,与大量关于慢性阻塞性肺疾病(COPD)的信息相比,ABECB的治疗缺乏研究,尽管这些病理之间存在精确的进化相关性,但ABECB经常被认为是矿石的易感初期。 ABECB是COPD患者就诊,住院和死亡的主要原因。该疾病的自然病程以发作发作的现象为特征(平均每年两次)。因此,必须防止加重,尽快治疗加重病,以最小化加重病对呼吸道和患者总体健康的不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号